{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain any sentences with a specific molecule name, a bioactivity metric (IC50, Ki, Kd, EC50), a numeric value for that metric, and a unit for that value. The text primarily describes methods and general properties of PEGylated interferon molecules."}
{"raw_mentions": "There are no sentences that meet the specified criteria, as none of the sentences contain a specific molecule name, ID, or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50, etc.), a specific numeric value for that metric, and a unit for that value."}
{"raw_mentions": "There are no sentences that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50 and their variations), a specific numeric value for that metric, and a unit for that value. The text primarily describes methods, calculations, and compositions in general terms, without providing specific bioactivity metrics and their corresponding values and units."}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain specific molecule names, bioactivity metrics (IC50, Ki, Kd, EC50), numeric values, and units. It appears to be a descriptive text about TNF antagonists, TNFR polypeptides, and their characteristics, without providing specific data or measurements."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nEffective dosages of an IFN-a range from about 3 \u03bcg to about 27 \u03bcg, from about 3 MU to about 10 MU, from about 90 \u03bcg to about 180 \u03bcg, or from about 18 \u03bcg \nEffective dosages of Infergen\u00ae consensus IFN-a include about 3 \u03bcg, about 6 \u03bcg, about 9 \u03bcg, about 12 \u03bcg, about 15 \u03bcg, about 18 \u03bcg, about 21 \u03bcg, about 24 \u03bcg, about 27 \u03bcg, or about 30 \u03bcg, of drag per dose.\nEffective dosages of IFN-a2a and IFN-a2b range from 3 million Units (MU) to 10 MU per dose.\nEffective dosages of PEGASYS\u00aePEGylated IFN-a2a contain an amount of about 90 \u03bcg to 270 \u03bcg, or about 180 \u03bcg, of drag per dose.\nEffective dosages of PEG-INTRON\u00aePEGylated IFN-a2b contain an amount of about 0.5 \u03bcg to 3.0 \u03bcg of drug per kg of body weight per dose.\nEffective dosages of PEGylated consensus interferon (PEG-CIFN) contain an amount of about 18 \u03bcg to about 90 \u03bcg, or from about 27 \u03bcg to about 60 \u03bcg, or about 45 \u03bcg, of CIFN amino acid weight per dose of PEG-CIFN.\nEffective dosages of monoPEG (30 kD, linear)-ylated CIFN contain an amount of about 45 \u03bcg to about 270 \u03bcg, or about 60 \u03bcg to about 180 \u03bcg, or about 90 \u03bcg to about 120 \u03bcg, of drug per dose."}
{"final_json": [{"molecule_name": "IFN-a", "protein_target_name": null, "binding_metric": null, "value": "3", "unit": "\u03bcg"}, {"molecule_name": "IFN-a", "protein_target_name": null, "binding_metric": null, "value": "27", "unit": "\u03bcg"}, {"molecule_name": "IFN-a", "protein_target_name": null, "binding_metric": null, "value": "3", "unit": "MU"}, {"molecule_name": "IFN-a", "protein_target_name": null, "binding_metric": null, "value": "10", "unit": "MU"}, {"molecule_name": "Infergen", "protein_target_name": null, "binding_metric": null, "value": "3", "unit": "\u03bcg"}, {"molecule_name": "Infergen", "protein_target_name": null, "binding_metric": null, "value": "6", "unit": "\u03bcg"}, {"molecule_name": "Infergen", "protein_target_name": null, "binding_metric": null, "value": "9", "unit": "\u03bcg"}, {"molecule_name": "Infergen", "protein_target_name": null, "binding_metric": null, "value": "12", "unit": "\u03bcg"}, {"molecule_name": "Infergen", "protein_target_name": null, "binding_metric": null, "value": "15", "unit": "\u03bcg"}, {"molecule_name": "Infergen", "protein_target_name": null, "binding_metric": null, "value": "18", "unit": "\u03bcg"}, {"molecule_name": "Infergen", "protein_target_name": null, "binding_metric": null, "value": "21", "unit": "\u03bcg"}, {"molecule_name": "Infergen", "protein_target_name": null, "binding_metric": null, "value": "24", "unit": "\u03bcg"}, {"molecule_name": "Infergen", "protein_target_name": null, "binding_metric": null, "value": "27", "unit": "\u03bcg"}, {"molecule_name": "Infergen", "protein_target_name": null, "binding_metric": null, "value": "30", "unit": "\u03bcg"}, {"molecule_name": "IFN-a2a", "protein_target_name": null, "binding_metric": null, "value": "3", "unit": "MU"}, {"molecule_name": "IFN-a2b", "protein_target_name": null, "binding_metric": null, "value": "10", "unit": "MU"}, {"molecule_name": "PEGASYS", "protein_target_name": null, "binding_metric": null, "value": "90", "unit": "\u03bcg"}, {"molecule_name": "PEGASYS", "protein_target_name": null, "binding_metric": null, "value": "270", "unit": "\u03bcg"}, {"molecule_name": "PEGASYS", "protein_target_name": null, "binding_metric": null, "value": "180", "unit": "\u03bcg"}, {"molecule_name": "PEG-INTRON", "protein_target_name": null, "binding_metric": null, "value": "0.5", "unit": "\u03bcg/kg"}, {"molecule_name": "PEG-INTRON", "protein_target_name": null, "binding_metric": null, "value": "3.0", "unit": "\u03bcg/kg"}, {"molecule_name": "PEG-CIFN", "protein_target_name": null, "binding_metric": null, "value": "18", "unit": "\u03bcg"}, {"molecule_name": "PEG-CIFN", "protein_target_name": null, "binding_metric": null, "value": "90", "unit": "\u03bcg"}, {"molecule_name": "PEG-CIFN", "protein_target_name": null, "binding_metric": null, "value": "27", "unit": "\u03bcg"}, {"molecule_name": "PEG-CIFN", "protein_target_name": null, "binding_metric": null, "value": "60", "unit": "\u03bcg"}, {"molecule_name": "PEG-CIFN", "protein_target_name": null, "binding_metric": null, "value": "45", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated CIFN", "protein_target_name": null, "binding_metric": null, "value": "45", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated CIFN", "protein_target_name": null, "binding_metric": null, "value": "270", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated CIFN", "protein_target_name": null, "binding_metric": null, "value": "60", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated CIFN", "protein_target_name": null, "binding_metric": null, "value": "180", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated CIFN", "protein_target_name": null, "binding_metric": null, "value": "90", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated CIFN", "protein_target_name": null, "binding_metric": null, "value": "120", "unit": "\u03bcg"}]}
{"raw_mentions": "There are no sentences that contain all four required components: \n1. A specific molecule name, ID or other identifier.\n2. A bioactivity metric IC50, Ki, Kd, EC50 and their variations.\n3. A specific numeric value for that metric (e.g., \"10\", \"5.5\", \"<100\").\n4. A unit for that value (e.g., \"nM\", \"uM\", \"%\").\n\nThe provided text snippet does not include any sentences that meet these criteria. It primarily discusses treatment regimens and dosages for HCV infection without referencing specific bioactivity metrics or their values with units."}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain specific molecule names, bioactivity metrics (IC50, Ki, Kd, EC50), numeric values, and units that are required for a sentence to be considered relevant. The text primarily discusses treatment methods, dosages, and combination therapies, but does not provide specific data that meets the criteria."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\n[0803] As non-limiting examples, any ofthe above-described methods featuring an IFN-a regimen may be modified to replace the subject IFN-a regimen with a regimen of INFERGEN\u00ae interferon alfacon-1 comprising administering a dosage of INFERGEN\u00ae interferon alfacon-1 containing an amount of 9 \u03bcg of drug per dose, subcutaneously once daily or three times per week for the desired treatment duration with an NS3 inhibitor compound.\n\n[0804] As non-limiting examples, any ofthe above-described methods featuring an IFN-a regimen may be modified to replace the subject IFN-a regimen with a regimen of INFERGEN\u00ae interferon alfacon-1 comprising administering a dosage of INFERGEN\u00ae interferon alfacon-1 containing an amount of 15 \u03bcg of drug per dose, subcutaneously once daily or three times per week for the desired treatment duration with an NS3 inhibitor compound.\n\n[0805] As non-limiting examples, any ofthe above-described methods featuring an IFN-? regimen may be modified to replace the subject IFN-? regimen with a regimen of IFN-? comprising administering a dosage of IFN-? containing an amount of 25 \u03bcg of drug per dose, subcutaneously three times per week for the desired treatment duration with an NS3 inhibitor compound.\n\n[0806] As non-limiting examples, any ofthe above-described methods featuring an IFN-? regimen may be modified to replace the subject IFN-? regimen with a regimen of IFN-? comprising administering a dosage of IFN-? containing an amount of 50 \u03bcg of drag per dose, subcutaneously three times per week for the desired treatment duration with an NS3 inhibitor compound.\n\n[0807] As non-limiting examples, any ofthe above-described methods featuring an TEN-? regimen may be modified to replace the subject IFN-? regimen with a regimen of IFN-? comprising administering a dosage of IFN-? containing an amount of 100 \u03bcg of drag per dose, subcutaneously three times per week for the desired treatment duration with an NS3 inhibitor compound.\n\n[0808] As non-limiting examples, any ofthe above-described methods featuring an IFN-a and IFN-? combination regimen may be modified to replace the subject IFN-a and IFN-? combination regimen with an IFN-a and IFN-? combination regimen comprising: (a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 100 \u03bcg of drug per dose, subcutaneously once weekly, once every 8 days, or once every 10 days; and (b) administering a dosage of IFN-? containing an amount of 50 \u03bcg of drag per dose, subcutaneously three times per week; for the desired treatment duration with an NS3 inhibitor compound.\n\n[0809] As non-limiting examples, any ofthe above-described methods featuring a TNF antagonist regimen may be modified to replace the subject TNF antagonist regimen with a TNF antagonist regimen comprising administering a dosage of a TNF antagonist selected from the group of: (a) etanercept in an amount of 25 mg of drug per dose subcutaneously twice per week, (b) infliximab in an amount of 3 mg of drug per kilogram of body weight per dose intravenously at weeks 0, 2 and 6, and every 8 weeks thereafter, or \n\n[0810] As non-limiting examples, any ofthe above-described methods featuring an IFN-a and IFN-? combination regimen can be modified to replace the subject IFN-a and IFN-? combination regimen with an IFN-a and IFN-? combination regimen comprising: (a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 100 \u03bcg of drug per dose, subcutaneously once weekly, once every 8 days, or once every 10 days; and (b) administering a dosage of IFN-? containing an amount of 100 \u03bcg of drug per dose, subcutaneously three times per week; for the desired treatment duration with an NS3 inhibitor compound.\n\n[0811] As non-limiting examples, any ofthe above-described methods featuring an IFN-a and IFN-? combination regimen may be modified to replace the subject IFN-a and IFN-? combination regimen with an IFN-a and IFN-? combination regimen comprising: (a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 150 \u03bcg of drug per dose, subcutaneously once weekly, once every 8 days, or once every 10 days; and (b) administering a dosage of IFN-? containing an amount of 50 \u03bcg of drug per dose, subcutaneously three times per week; for the desired treatment duration with an NS3 inhibitor compound.\n\n[0812] As non-limiting examples, any ofthe above-described methods featuring an IFN-a and IFN-? combination regimen may be modified to replace the subject IFN-a and IFN-? combination regimen with an IFN-a and IFN-? combination regimen comprising: (a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 150 \u03bcg of drag per dose, subcutaneously once weekly, once every 8 days, or once every 10 days; and (b) administering a dosage of IFN-? containing an amount of 100 \u03bcg of drag per dose, subcutaneously three times per week; for the desired treatment duration with an NS3 inhibitor compound.\n\n[0813] As non-limiting examples, any ofthe above-described methods featuring an IFN-a and IFN-? combination regimen maybe modified to replace the subject IFN-a and IFN-? combination regimen with an IFN-a and IFN-? combination regimen comprising: (a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 200 \u03bcg of drug per dose, subcutaneously once weekly, once every 8 days, or once every 10 days; and (b) administering a dosage of IFN-? containing an amount of 50 \u03bcg of drug per dose, subcutaneously three times per week; for the desired treatment duration with an NS3 inhibitor compound.\n\n[0814] As non-limiting examples, any of the above-described methods featuring an IFN-a and IFN-? combination regimen may be modified to replace the subject IFN-a and IFN-? combination regimen with an IFN-a and IFN-? combination regimen comprising: (a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 200 \u03bcg of drag per dose, subcutaneously once weekly, once every 8 days, or once every 10 days; and (b) administering a dosage of IFN-? containing an amount of 100 \u03bcg of drug per dose, subcutaneously three times per week; for the desired treatment duration with an NS3 inhibitor compound.\n\n[0815] As non-limiting examples, any ofthe above-described methods featuring an IFN-a and IFN-? combination regimen maybe modified to replace the subject IFN-a and IFN-? combination regimen with an IFN-a and IFN-? combination regimen comprising: (a) administering a dosage of INFERGEN\u00ae interferon alfacon-1 containing an amount of 9 \u03bcg of drug per dose, subcutaneously three times per week; and (b) administering a dosage of IFN-? containing an amount of 25 \u03bcg of drag per dose, subcutaneously three times per week; for the desired treatment duration with an NS3 inhibitor compound.\n\n[0816] As non-limiting examples, any ofthe above-described methods featuring an IFN-a and IFN-? combination regimen maybe modified to replace the subject IFN-a and IFN-? combination regimen with an IFN-a and IFN-? combination regimen comprising: (a) administering a dosage of INFERGEN\u00ae interferon alfacon-1 containing an amount of 9 \u03bcg of drag per dose, subcutaneously three times per week; and (b) administering a dosage of IFN-? containing an amount of 50 \u03bcg of drag per dose, subcutaneously three times per week; for the desired treatment duration with an NS3 inhibitor compound."}
{"final_json": [{"molecule_name": "INFERGEN\u00ae interferon alfacon-1", "protein_target_name": null, "binding_metric": null, "value": "9", "unit": "\u03bcg"}, {"molecule_name": "INFERGEN\u00ae interferon alfacon-1", "protein_target_name": null, "binding_metric": null, "value": "15", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "25", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "50", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "50", "unit": "\u03bcg"}, {"molecule_name": "etanercept", "protein_target_name": "TNF", "binding_metric": null, "value": "25", "unit": "mg"}, {"molecule_name": "infliximab", "protein_target_name": "TNF", "binding_metric": null, "value": "3", "unit": "mg/kg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "150", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "50", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "150", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "200", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "50", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "200", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "INFERGEN\u00ae interferon alfacon-1", "protein_target_name": null, "binding_metric": null, "value": "9", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "25", "unit": "\u03bcg"}, {"molecule_name": "INFERGEN\u00ae interferon alfacon-1", "protein_target_name": null, "binding_metric": null, "value": "9", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "50", "unit": "\u03bcg"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\n(a) administering a dosage of F FERGEN\u00ae interferon alfacon-1 containing an amount of 15 \u03bcg of drag per dose, subcutaneously once daily; \n(a) administering a dosage of INFERGEN\u00ae interferon alfacon-1 containing an amount of 15 \u03bcg of drag per dose, subcutaneously once daily; \n(a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 100 \u03bcg of drug per dose, \n(a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 100 \u03bcg of drag per dose, \n(a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 150 \u03bcg of drug per dose, \n(a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 150 \u03bcg of drag per dose, \n(a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 200 \u03bcg of drag per dose, \n(a) administering a dosage of monoPEG (30 kD, linear)-ylated consensus IFN-a containing an amount of 200 \u03bcg of drug per dose, \n(a) administering a dosage of INFERGEN\u00ae interferon alfacon-1 containing an amount of 9 \u03bcg of drug per dose, subcutaneously three times per week; \n(b) administering a dosage of IFN-? containing an amount of 50 \u03bcg of drag per dose, subcutaneously three times per week; \n(b) administering a dosage of IFN-? containing an amount of 100 \u03bcg of drug per dose, subcutaneously three times per week; \n(b) administering a dosage of IFN-? containing an amount of 50 \u03bcg of drug per dose, subcutaneously three times per week; \n(b) administering a dosage of IFN-? containing an amount of 100 \u03bcg of drag per dose, subcutaneously three times per week; \n(b) administering a dosage of IFN-? containing an amount of 25 \u03bcg of drag per dose, subcutaneously three times per week; \n(c) administering a dosage of a TNF antagonist selected from (i) etanercept in an amount of 25 mg subcutaneously twice per week, \n(c) administering a dosage of a TNF antagonist selected from (i) etanercept in an amount of 25 mg subcutaneously twice per week, \n(c) administering a dosage of a TNF antagonist selected from (i) etanercept in an amount of 25 mg subcutaneously twice per week, \n(c) administering a dosage of a TNF antagonist selected from (i) etanercept in an amount of 25 mg subcutaneously twice per week, \n(c) administering a dosage of a TNF antagonist selected from (i) etanercept in an amount of 25 mg subcutaneously twice per week, \n(c) administering a dosage of a TNF antagonist selected from (i) etanercept in an amount of 25 mg subcutaneously twice per week, \n(c) administering a dosage of a TNF antagonist selected from (i) etanercept in an amount of 25 mg subcutaneously twice per week, \n(i) etanercept in an amount of 25 mg subcutaneously twice per week, \n(i) infliximab in an amount of 3 mg of drug per kilogram of body weight intravenously at weeks 0, 2 and 6, and every 8 weeks thereafter \n(iii) adahmumab in an amount of 40 mg subcutaneously once weekly or once every other week;"}
{"final_json": [{"molecule_name": "FERGEN\u00ae interferon alfacon-1", "protein_target_name": null, "binding_metric": null, "value": "15", "unit": "\u03bcg"}, {"molecule_name": "INFERGEN\u00ae interferon alfacon-1", "protein_target_name": null, "binding_metric": null, "value": "15", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "150", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "150", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "200", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "200", "unit": "\u03bcg"}, {"molecule_name": "INFERGEN\u00ae interferon alfacon-1", "protein_target_name": null, "binding_metric": null, "value": "9", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "50", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "50", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "25", "unit": "\u03bcg"}, {"molecule_name": "etanercept", "protein_target_name": "TNF", "binding_metric": null, "value": "25", "unit": "mg"}, {"molecule_name": "etanercept", "protein_target_name": "TNF", "binding_metric": null, "value": "25", "unit": "mg"}, {"molecule_name": "etanercept", "protein_target_name": "TNF", "binding_metric": null, "value": "25", "unit": "mg"}, {"molecule_name": "etanercept", "protein_target_name": "TNF", "binding_metric": null, "value": "25", "unit": "mg"}, {"molecule_name": "etanercept", "protein_target_name": "TNF", "binding_metric": null, "value": "25", "unit": "mg"}, {"molecule_name": "etanercept", "protein_target_name": "TNF", "binding_metric": null, "value": "25", "unit": "mg"}, {"molecule_name": "etanercept", "protein_target_name": "TNF", "binding_metric": null, "value": "25", "unit": "mg"}, {"molecule_name": "etanercept", "protein_target_name": "TNF", "binding_metric": null, "value": "25", "unit": "mg"}, {"molecule_name": "infliximab", "protein_target_name": "TNF", "binding_metric": null, "value": "3", "unit": "mg/kg"}, {"molecule_name": "adahmumab", "protein_target_name": "TNF", "binding_metric": null, "value": "40", "unit": "mg"}]}
{"raw_mentions": "Here are the extracted sentences:\n\n\n(a) administering a dosage of INFERGEN\u00ae interferon alfacon-1 containing an amount of 15 \u03bcg of drag per dose, subcutaneously once daily; \n(a) administering a dosage of IFN-? containing an amount of 100 \u03bcg of drug per dose, subcutaneously three times per week; \n(a) administering a dosage of monoPEG (30 kD, linear)- ylated consensus IFN-a containing an amount of 100 \u03bcg of drug per dose, subcutaneously once weekly, once every 8 days, or once every 10 days; \n(a) administering a dosage of monoPEG (30 kD, linear)- ylated consensus IFN-a containing an amount of 150 \u03bcg of drag per dose, subcutaneously once weekly, once every 8 days, or once every 10 days; \n(a) administering a dosage of monoPEG (30 kD, linear)- ylated consensus IFN-a containing an amount of 200 \u03bcg of drug per dose, subcutaneously once weekly, once every 8 days, or once every 10 days; \n(a) administering a dosage of INFERGEN\u00ae interferon alfacon-1 containing an amount of 9 \u03bcg of drag per dose, subcutaneously once daily or three times per week; \n(i) etanercept in an amount of 25 mg subcutaneously twice per week, \n(ii) infliximab in an amount of 3 mg of drag per kilogram of body weight intravenously at weeks 0, 2 and 6, and every 8 weeks thereafter \n(iii) adahmumab in an amount of 40 mg subcutaneously once weekly or once every other week;"}
{"final_json": [{"molecule_name": "INFERGEN\u00ae interferon alfacon-1", "protein_target_name": null, "binding_metric": null, "value": "15", "unit": "\u03bcg"}, {"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "150", "unit": "\u03bcg"}, {"molecule_name": "monoPEG (30 kD, linear)-ylated consensus IFN-a", "protein_target_name": null, "binding_metric": null, "value": "200", "unit": "\u03bcg"}, {"molecule_name": "INFERGEN\u00ae interferon alfacon-1", "protein_target_name": null, "binding_metric": null, "value": "9", "unit": "\u03bcg"}, {"molecule_name": "etanercept", "protein_target_name": null, "binding_metric": null, "value": "25", "unit": "mg"}, {"molecule_name": "infliximab", "protein_target_name": null, "binding_metric": null, "value": "3", "unit": "mg/kg"}, {"molecule_name": "adahmumab", "protein_target_name": null, "binding_metric": null, "value": "40", "unit": "mg"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nAs non-limiting examples, any of the above-described methods featuring an TEN-? and TNF antagonist combination regimen may be modified to replace the subject IFN-? and TNF antagonist combination regimen with an IFN-? and TNF antagonist combination regimen comprising: (a) administering a dosage of IFN-? containing an amount of 100 \u03bcg of drug per dose, subcutaneously three times per week; and (b) administering a dosage of a TNF antagonist selected from (i) etanercept in an amount of 25 mg subcutaneously twice per week, (ii) infliximab in an amount of 3 mg of drug per kilogram of body weight intravenously at weeks 0, 2 and 6, and every 8 weeks thereafter or (iii) adahmumab in an amount of 40 mg subcutaneously once weekly or once every other week; for the desired treatment duration with an NS3 inhibitor compound.\nAs non-limiting examples, any of the above-described methods that includes a regimen of monoPEG (30 kD, linear)-ylated consensus IFN-a may be modified to replace the regimen of monoPEG (30 kD, linear)-ylated consensus IFN-a with a regimen of peginterferon alfa-2a comprising administering a dosage of peginterferon alfa-2a containing an amount of 180 \u03bcg of drag per dose, subcutaneously once weekly for the desired treatment duration with an NS3 inhibitor compound.\nAs non-limiting examples, any of the above-described methods that includes a regimen of monoPEG (30 kD, linear)-ylated consensus IFN-a may be modified to replace the regimen of monoPEG (30 kD, linear)-ylated consensus IFN-a with a regimen of peginterferon alfa-2b comprising administering a dosage of peginterferon alfa-2b containing an amount of 1.0 \u03bcg to 1.5 \u03bcg of drag per kilogram of body weight per dose, subcutaneously once or twice weekly for the desired treatment duration with an NS3 inhibitor compound.\nAs non-limiting examples, any of the above-described methods may be modified to include administering a dosage of ribavirin containing an amount of 400 mg, 800 mg, 1000 mg or 1200 mg of drug orally per day, optionally in two or more divided doses per day, for the desired treatment duration with an NS3 inhibitor compound.\nAs non-limiting examples, any of the above-described methods may be modified to include administering a dosage of ribavirin containing (i) an amount of 1000 mg of drug orally per day for patients having a body weight of less than 75 kg or (ii) an amount of 1200 mg of drag orally per day for patients having a body weight of greater than or equal to 75 kg, optionally in two or more divided doses per day, for the desired treatment duration with an NS3 inhibitor compound.\nAs non-limiting examples, any of the above-described methods may be modified to replace the subject NS3 inhibitor regimen with an NS3 inhibitor regimen comprising administenng a dosage of 0.01 mg to 0.1 mg of drag per kilogram of body weight orally daily, optionally in two or more divided doses per day, for the desired treatment duration with th"}
{"final_json": [{"molecule_name": "IFN-?", "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "etanercept", "protein_target_name": "TNF", "binding_metric": null, "value": "25", "unit": "mg"}, {"molecule_name": "infliximab", "protein_target_name": "TNF", "binding_metric": null, "value": "3", "unit": "mg/kg"}, {"molecule_name": "adahmumab", "protein_target_name": "TNF", "binding_metric": null, "value": "40", "unit": "mg"}, {"molecule_name": "peginterferon alfa-2a", "protein_target_name": null, "binding_metric": null, "value": "180", "unit": "\u03bcg"}, {"molecule_name": "peginterferon alfa-2b", "protein_target_name": null, "binding_metric": null, "value": "1.0-1.5", "unit": "\u03bcg/kg"}, {"molecule_name": "ribavirin", "protein_target_name": null, "binding_metric": null, "value": "400-1200", "unit": "mg"}, {"molecule_name": "ribavirin", "protein_target_name": null, "binding_metric": null, "value": "1000", "unit": "mg"}, {"molecule_name": "ribavirin", "protein_target_name": null, "binding_metric": null, "value": "1200", "unit": "mg"}, {"molecule_name": "NS3 inhibitor", "protein_target_name": "NS3", "binding_metric": null, "value": "0.01-0.1", "unit": "mg/kg"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nFull-length E. coli NS3 - 2.03 \u03bcM \nFull-length BV NS3 - 1.74 \u03bcM \nThe RETS1 substrate was diluted to 8 \u03bcM (1:80.75 of 646 \u03bcM stock - 65 \u03bcL 646 \u03bcM stock + 5184 \u03bcL assay buffer).\nInhibitors were made as a 10X stock in Assay Medium, (3 -fold dilutions from 10 \u03bcM to 56pM final concentration, final DMSO concentration 1%)"}
{"final_json": [{"molecule_name": "E. coli NS3", "protein_target_name": null, "binding_metric": null, "value": "2.03", "unit": "\u03bcM"}, {"molecule_name": "BV NS3", "protein_target_name": null, "binding_metric": null, "value": "1.74", "unit": "\u03bcM"}, {"molecule_name": "RETS1 substrate", "protein_target_name": null, "binding_metric": null, "value": "8", "unit": "\u03bcM"}, {"molecule_name": "RETS1 substrate", "protein_target_name": null, "binding_metric": null, "value": "646", "unit": "\u03bcM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "10", "unit": "\u03bcM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "56", "unit": "pM"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nCompounds AR294381, AR261408, AR333833 and AR334191 yielded replicon EC50 values of approximately 2 nM and exhibited stability in vitro in rat, dog and human hepatocyte incubation assays, which data would predict low to moderate rates of clearance from liver.\nFor compounds AR294381, AR261408, AR333833 and AR334191, a single 30 mg/kg oral dose in Rattus sp. yielded concentrations in liver at 24 hours post dose that were at least 200-fold more than their respective replicon EC50 values.\nAt a clinically more reasonable oral dose (3 mg/kg), compound AR334191 yielded a concentration in liver at 8 hours post dose that was over 100-fold more than the replicon EC50 value of the compound.\nCompound AR334191 did not display toxicity in Rattus sp. when dosed for seven days at 30 mg/kg BID, providing at least a 10-fold safety margin above the presumptive efficacious dose (3 mg/kg) that yields liver concentrations 100-fold in excess ofthe replicon EC50 value ofthe compound."}
{"final_json": [{"molecule_name": "AR294381", "protein_target_name": null, "binding_metric": "EC50", "value": "2", "unit": "nM"}, {"molecule_name": "AR261408", "protein_target_name": null, "binding_metric": "EC50", "value": "2", "unit": "nM"}, {"molecule_name": "AR333833", "protein_target_name": null, "binding_metric": "EC50", "value": "2", "unit": "nM"}, {"molecule_name": "AR334191", "protein_target_name": null, "binding_metric": "EC50", "value": "2", "unit": "nM"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nFull-length E. coli \u039dS3 - 2.03 \u03bcM \nFull-length BV NS3 - 1.74\u03bcM \nThe RETSl substrate was diluted to 8\u03bcM (1:80.75 of 646\u03bcM stock - 65\u03bcL 646\u03bcM stock + 5184\u03bcL assay buffer) \nCells were maintained at 37\u00b0C, 5%CO<sub>2</sub>, in DMEM (Gibco 11965- 092) supplemented with L-glutamine 200mM (100X) (Gibco25030-081) \nInhibitors were made as a 10X stock in Assay Medium, (3-fold dilutions from lO\u03bcM to 56pM final concentration, final DMSO concentration 1%)"}
{"final_json": [{"molecule_name": "E. coli \u039dS3", "protein_target_name": null, "binding_metric": null, "value": "2.03", "unit": "\u03bcM"}, {"molecule_name": "BV NS3", "protein_target_name": null, "binding_metric": null, "value": "1.74", "unit": "\u03bcM"}, {"molecule_name": "RETSl substrate", "protein_target_name": null, "binding_metric": null, "value": "8", "unit": "\u03bcM"}, {"molecule_name": "RETSl substrate", "protein_target_name": null, "binding_metric": null, "value": "646", "unit": "\u03bcM"}, {"molecule_name": "L-glutamine", "protein_target_name": null, "binding_metric": null, "value": "200", "unit": "mM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "10", "unit": "\u03bcM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "56", "unit": "pM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "1", "unit": "%"}]}
{"raw_mentions": "Here are the extracted sentences:\n\nCompound AR334187 yielded a replicon EC50 value of approximately 2 nM and exhibited stability in vitro in rat, dog and human hepatocyte incubation assays, which data would predict low to moderate rates of clearance from liver.\nIn addition, this compound displayed a high degree of selectivity against a panel of other serine proteases, and no significant inhibition of Cytochrome P450 isoforms or hERG channel activity at even the highest concentrations tested (10 \u03bcM).\nFor compound AR334187, a single 30 mg/kg oral dose in Rattus sp. yielded a concentration in liver at 24 hours post dose that was at least 200-fold more than the compound's replicon EC50 value.\nAt a clinically more reasonable oral dose (3 mg/kg), compound AR334187 yielded a concentration in liver at 8 hours post dose that was over 100-fold more than the replicon EC50 value of the compound.\nCompound AR334187 did not display toxicity in Rattus sp. when dosed for seven days at 30 mg/kg BID, providing at least a 10-fold safety margin above the presumptive efficacious dose (3 mg kg) that yields liver concentrations 100-fold in excess ofthe replicon EC50 value ofthe compound."}
{"final_json": [{"molecule_name": "AR334187", "protein_target_name": null, "binding_metric": "EC50", "value": "2", "unit": "nM"}, {"molecule_name": "AR334187", "protein_target_name": "Cytochrome P450", "binding_metric": null, "value": "<10", "unit": "\u03bcM"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nA indicates an IC50 of less than 10 \u03bcM \nB  indicates an IC50 of less than 1 \u03bcM and C indicates an IC50 of less the 0.1 \u03bcM\nFull-length E. coli NS3 - 2.03\u03bcM Full-length BV NS3 - 1.74\u03bcM where Ki = IC50/(1+[S]/Km))\nDilute RETSl substrate to 8\u03bcM (1:80.75 of 646\u03bcM stock - 65\u03bcL 646\u03bcM stock + 5184\u03bcL assay buffer)"}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50", "value": "<10", "unit": "\u03bcM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50", "value": "<1", "unit": "\u03bcM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50", "value": "<0.1", "unit": "\u03bcM"}, {"molecule_name": null, "protein_target_name": "E. coli NS3", "binding_metric": "IC50", "value": "2.03", "unit": "\u03bcM"}, {"molecule_name": null, "protein_target_name": "BV NS3", "binding_metric": "IC50", "value": "1.74", "unit": "\u03bcM"}, {"molecule_name": "RETSl substrate", "protein_target_name": null, "binding_metric": null, "value": "8", "unit": "\u03bcM"}, {"molecule_name": "RETSl substrate", "protein_target_name": null, "binding_metric": null, "value": "646", "unit": "\u03bcM"}]}
